News | August 01, 2023
Concord Biotech’s IPO to open on 4th August, 2023
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
The company expects to capture a 10 per cent share in Spain’s $6.34 million meropenem market and consolidate its position in other European countries
The company expects this approval in Baddi to pave the way for GMP certifications from European Medicines Agency and other PIC/S member nations
The approval paves the way for consolidating the company’s position in Kenya and other African markets as part of its global expansion plans
Leading Research-driven Pharma Company Combats Antibiotic Resistance and Demonstrates Innovation in Medical Solutions
The company moves a step closer towards achieving its goal of emerging as the top oncology medicine supplier from India in the ASEAN region
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
Healthcare leaders are heavily investing in AI or plan to do so for both critical decision support and operational efficiency, helping tackle staff shortages
Digitization has unleashed a flood of data that presents a huge opportunity but is also overwhelming clinicians, nurses, and administrators
Subscribe To Our Newsletter & Stay Updated
